Postoperative Radioactive Iodine Ablation Effective in Reducing Disease Recurrence in Low-Risk Thyroid CancerJune 20, 2018
For patients with low-risk thyroid cancer, ablation when indicated could be achieved with 1.1 GBq radioactive iodine after recombinant human thyroid-stimulating hormone (rhTSH) injections, as this combination reduces whole body irradiation and maintains quality of life.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Evidence suggests that neoadjuvant chemoradiotherapy may afford benefit, but this hypothesis requires further validation.
Previous studies demonstrated that FOLFIRINOX is more effective than gemcitabine as first-line treatment for patients with metastatic pancreatic cancer with good performance status.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Insulin Pen Devices comparison chart for patients with diabetes mellitus.
Preoperative Chemotherapy May Improve Margin-negative Resection Rates, Survival Outcomes in Pancreatic CancerMay 04, 2018
Researchers enrolled 50 previously untreated patients with newly diagnosed and borderline resectable pancreatic cancer.
Insulin products table with pharmacokinetic properties.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
In the future, targets of drug development may be within the microbiome.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
The addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Find current treatment regimens for rare thymomas and thymic carcinomas, including options such as carboplatin + paclitaxel and more.
Lutetium Lu 177 dotatate binds to somatostatin receptors to deliver radiation directly into tumor cells.
Thymic carcinomas typically express high levels of PD-L1, leading researchers to predict a positive response to pembrolizumab.
Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic cancer.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Resveratrol and Cancer
- Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
- Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
- ARID1A Mutations Might Predict Tumor Response to Immunotherapy
- Global Burden of Myeloma Increasing, Access to Treatments Lacking
- ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks
- Adding Rituximab to Prednisolone May Improve Long-Term Response in Immune Thrombocytopenia
- FDA Updates Restrictions for Pembrolizumab, Atezolizumab in Urothelial Carcinoma
- Longer Overall Survival with FOLFIRINOX Versus Gemcitabine/nab-Paclitaxel in Pancreatic Cancer
- Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer